Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Function-Friendly Semi-Fowler Positioning for Coronary Angiography and PCI

12 de novembro de 2026 atualizado por: Shanghai Zhongshan Hospital

Pilot Study on the Feasibility and Safety of Function-Friendly Semi-Fowler Positioning in Coronary Angiography and Percutaneous Coronary Intervention

This study will assess whether planned coronary angiography (CAG), and simple percutaneous coronary intervention (PCI) when needed, can be completed safely and technically while participants are in a semi-sitting position with the head of the procedure table raised to 60 degrees. Ten clinically stable adults scheduled for an elective procedure are planned. The first stage will include participants undergoing CAG. After a safety review, the study may include participants expected to need only simple PCI. Heart rhythm, blood pressure, and blood oxygen will be monitored continuously. If predefined safety criteria occur, staff will lower the table or return the participant to a flat position and provide usual clinical care. Researchers will describe procedure completion, image quality, radiation exposure, contrast use, tolerance of the position, and safety events through 3 days after the procedure. This exploratory study is not designed to establish treatment efficacy.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

This is a prospective, single-center, open-label, single-arm, staged early-feasibility study at Zhongshan Hospital, Fudan University. The planned enrollment is 10 participants aged 18 to 75 years. Eligible participants are clinically stable and scheduled for elective transradial CAG or planned simple PCI, and can tolerate a monitored 60-degree semi-Fowler position for at least 10 minutes before the procedure. The first stage prioritizes CAG. Participants expected to need only simple PCI may be enrolled only after a safety review confirms that the workflow is executable without unacceptable risk. During CAG and, when clinically indicated, simple PCI, the procedure table will be raised to a default head elevation of 60 degrees. ECG, blood pressure, and oxygen saturation will be monitored continuously. If chest pain, significant dyspnea, persistent oxygen saturation below 90%, systolic blood pressure below 90 mmHg or a decrease of at least 30% requiring intervention, sustained ventricular tachycardia or fibrillation, cerebral hypoperfusion, equipment collision, catheter or tubing traction, or another predefined safety concern occurs, the positioning intervention will stop and the table will be lowered or the participant returned to 0-degree supine; usual clinical care will take priority. CAG and PCI technical success will be described among participants undergoing the respective procedure. Safety events will be collected from the start of the positioning intervention through 3 days after the procedure. Other measures include image quality, completion of standard projections, fluoroscopy time, dose-area product, contrast volume, procedure duration, positioning changes, and tolerance. No investigational drug is used. The commercial angiography X-ray system is used as a carrier for the positioning intervention; the study does not modify or evaluate the device.

Tipo de estudo

Intervencional

Inscrição (Estimado)

10

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Shanghai, China
        • Zhongshan Hospital, Fudan University
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Age 18 to 75 years.
  2. Clinically stable and scheduled for elective coronary angiography (CAG) or planned simple percutaneous coronary intervention (PCI), with no ongoing resting ischemia.
  3. Meets clinical indications for coronary angiography or intervention, with ischemic evidence consistent with coronary artery disease based on symptoms, ECG, or noninvasive imaging.
  4. Planned radial access; the operator expects the procedure can be performed using standard catheters and devices.
  5. Able to tolerate a monitored 60-degree semi-Fowler position for at least 10 minutes before the procedure.
  6. Body size, weight, shoulder width, and range of motion are within equipment and support-system limits, and the participant can be secured using the manufacturer-approved fixation system.
  7. Able to understand the study and provide written informed consent.

Exclusion Criteria:

  1. Pregnant or breastfeeding, or the participant or spouse plans pregnancy within the next 6 months.
  2. Known contraindication to local anesthetic or history of severe contrast-media allergy.
  3. Neurologic or psychiatric disease or language impairment that prevents effective communication or cooperation.
  4. Serious comorbidity with expected survival less than 6 months.
  5. Uncontrolled hypertension (screening systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg) or baseline systolic blood pressure <100 mmHg.
  6. Acute coronary syndrome, ongoing ischemia, hemodynamic instability, cardiogenic shock, or need for emergency CAG/PCI.
  7. Decompensated heart failure, left ventricular ejection fraction <30%, inability to maintain oxygenation at rest, or estimated glomerular filtration rate <30 mL/min/1.73 m^2.
  8. Known or highly suspected high-risk left main disease, chronic total occlusion, complex bifurcation disease, severe calcification, or other anatomy expected to require complex PCI.
  9. Platelet count <50 × 10^9/L or coagulation results outside the institution usual acceptable range.
  10. Participation in another clinical trial or research study within 2 months before screening.
  11. Back pain, stiffness, limited mobility, or injury preventing tolerance of transition from supine to the study position.
  12. Inability to secure the torso reliably, inability to complete the pre-procedure positioning-tolerance test, or investigator judgment that emergency return to supine may be restricted.
  13. Any other condition for which the investigator considers participation unsafe.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Function-Friendly Semi-Fowler Positioning

All participants receive the same positioning intervention during elective transradial CAG and, if clinically indicated, simple PCI. The procedure table is raised to a default head elevation of 60 degrees, with continuous ECG, blood pressure, and oxygen saturation monitoring. If predefined safety concerns occur, the table angle is lowered or the participant is returned to 0-degree supine and usual clinical care is provided.

The procedure table head is elevated to a default 60-degree semi-Fowler position during elective transradial coronary angiography and, if clinically indicated, simple PCI. ECG, blood pressure, and oxygen saturation are continuously monitored. If predefined safety criteria occur, the table angle is reduced or the participant is immediately returned to 0-degree supine and usual clinical care is provided. The commercial angiography X-ray system and adjustable procedure table are used as available clinical equipment; no device hardware, software, collision protection, interlocks, image processing, or dose-control functions are modified or evaluated.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of Participants With Coronary Angiography (CAG) Technical Success
Prazo: During the CAG procedure

The number of participants undergoing CAG who complete the planned CAG in the prespecified semi-Fowler position without position-related unplanned return to supine or substantial angle reduction, procedure discontinuation, access-site change, missing key projections, or participant/equipment collision, and whose images are independently confirmed to be diagnostic, divided by the number of participants undergoing CAG.

During the CAG procedure
Proportion of Participants With Percutaneous Coronary Intervention (PCI) Technical Success
Prazo: During the PCI procedure

Among participants who undergo PCI, the proportion who complete planned device delivery, treatment, and withdrawal while meeting the protocol-defined positioning and safety requirements. PCI success is calculated using participants who undergo PCI as the denominator.

During the PCI procedure
Participants With Position-Related Serious Adverse Events or Prespecified Safety Events
Prazo: From the start of the positioning intervention through 3 days after the procedure

Number and proportion of participants experiencing a position-related serious adverse event or any prespecified safety event: hemodynamic instability, hypoxia, sustained arrhythmia, cerebral hypoperfusion, unplanned respiratory or circulatory support, mechanical collision, or emergency return to supine.

From the start of the positioning intervention through 3 days after the procedure

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Diagnostic Acceptability of Coronary Angiography Images
Prazo: During the procedure

Coronary angiography and fluoroscopy image quality rated on a 1-to-3 Likert scale; a score of 2 or 3 is acceptable. Images are assessed by two independent physicians, with adjudication by a third if needed.

During the procedure
Completion of Standard Coronary Angiographic Views and Visualization of Major Coronary Segments
Prazo: During the procedure

Completion of standard left anterior oblique, right anterior oblique, cranial, and caudal projections, and the ability to visualize the left anterior descending, left circumflex, and right coronary arteries and their major branches.

During the procedure
Total Fluoroscopy Time
Prazo: During the procedure

Total fluoroscopy time recorded during the CAG and, if performed, PCI procedure.

During the procedure
Dose-Area Product (DAP)
Prazo: During the procedure

Dose-area product and other radiation dose parameters recorded by the angiography system.

During the procedure
Contrast Volume
Prazo: During the procedure

Total contrast-media volume administered during the procedure.

During the procedure
Procedure Duration
Prazo: During the procedure

Total duration of the CAG procedure and, if performed, PCI procedure, recorded as specified in the study CRF.

During the procedure
Positioning Tolerance and Adjustments
Prazo: During the procedure

Table-head angle, number and reasons for position adjustments, participant symptoms, unplanned return to 0-degree supine, and equipment collision events.

During the procedure
Access and Device Delivery Completion
Prazo: During the procedure

Successful radial artery access and completion of planned device delivery and withdrawal, as applicable to the procedure performed.

During the procedure

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Junbo Ge, Fudan University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

25 de novembro de 2026

Conclusão Primária (Estimado)

1 de maio de 2028

Conclusão do estudo (Estimado)

1 de novembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

12 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

The protocol states that any data sharing must use de-identified data and receive the required approvals. Whether individual participant data will be shared, and the timing, access process, and supporting information, have not yet been determined.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever